Bayer proposes $10.25 billion plan for all Roundup cancer cases

17.02.26 18:32 Uhr

Werte in diesem Artikel
Aktien

39,58 EUR -0,15 EUR -0,38%

Indizes

PKT PKT

PKT PKT

1.978,4 PKT -10,8 PKT -0,54%

2.039,6 PKT -11,5 PKT -0,56%

23.168,1 PKT -130,8 PKT -0,56%

8.634,5 PKT -67,5 PKT -0,78%

1.814,0 PKT -25,7 PKT -1,40%

584,1 PKT 0,8 PKT 0,14%

219,4 PKT 0,3 PKT 0,14%

609,5 PKT -2,7 PKT -0,44%

5.692,9 PKT -39,9 PKT -0,70%

12.265,4 PKT -73,6 PKT -0,60%

23.213,0 PKT -95,0 PKT -0,41%

23.146,7 PKT -107,5 PKT -0,46%

17.959,4 PKT -14,6 PKT -0,08%

8.944,7 PKT -54,0 PKT -0,60%

23.214,8 PKT -100,9 PKT -0,43%

BERLIN — Bayer said on Tuesday that its Monsanto unit had filed a proposed U.S. class settlement totalling as much as $7.25 billion that was aimed at resolving current and future claims that its Roundup weedkiller caused Non-Hodgkins lymphoma. The German company said the proposed nationwide settlement, filed in the Circuit Court of the City of St. Louis, Missouri, would establish a long-term claims programme funded by capped annual payments over up to 21 years. Bayer, which has been dogged by the Roundup claims for years after buying Monsanto, said it is separately preparing additional settlements covering existing U.S. Roundup cases worth about $3 billion. The proposed settlement will cover the majority of cases pending in both U.S. state and federal courts. The proposal is slated to be filed before a judge in St. Louis, Missouri on Tuesday and will require approval by a judge. The proposal includes a provision allowing people who can prove that they have been diagnosed with Non-Hodgkins lymphoma and were exposed to Roundup before Tuesday to file claims to receive a portion of the setWeiter zum vollständigen Artikel bei Korea Times

Quelle: Korea Times

Nachrichten zu Bayer

Analysen zu Bayer

DatumRatingAnalyst
30.03.2026Bayer OverweightBarclays Capital
26.03.2026Bayer BuyUBS AG
16.03.2026Bayer OverweightBarclays Capital
16.03.2026Bayer BuyGoldman Sachs Group Inc.
16.03.2026Bayer BuyUBS AG
DatumRatingAnalyst
30.03.2026Bayer OverweightBarclays Capital
26.03.2026Bayer BuyUBS AG
16.03.2026Bayer OverweightBarclays Capital
16.03.2026Bayer BuyGoldman Sachs Group Inc.
16.03.2026Bayer BuyUBS AG
DatumRatingAnalyst
05.03.2026Bayer HoldDeutsche Bank AG
05.03.2026Bayer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
04.03.2026Bayer HoldJefferies & Company Inc.
25.02.2026Bayer NeutralUBS AG
18.02.2026Bayer NeutralUBS AG
DatumRatingAnalyst
18.02.2026Bayer VerkaufenDZ BANK
31.10.2019Bayer VerkaufenIndependent Research GmbH
21.08.2019Bayer VerkaufenIndependent Research GmbH
01.08.2019Bayer VerkaufenIndependent Research GmbH
28.06.2019Bayer VerkaufenIndependent Research GmbH

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Bayer nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen